ReviewGenes2023
MiT/TFE Family Renal Cell Carcinoma.
Review in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study.Cancer medicine · 2026Article
- The Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC.Neoplasia (New York, N.Y.) · 2026Article
- LncRNA FTX promotes myocardial fibrosis by sponging miR-335-3p to regulate TFEC/ILK signaling.Scientific reports · 2026Article
- Papillary Renal Neoplasm with Reversed Polarity in a 64-Year-Old Male: A Rare Case Report and Review of the Literature.International medical case reports journal · 2026Article
- New Insights into TFEB SUMOylation and Its Role in Lipid Metabolism and Cardiovascular Disease.International journal of molecular sciences · 2025Review
- Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching.World journal of urology · 2025Article
- RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma.Nature communications · 2025Article
- A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features.BJC reports · 2025Article
- Mechanistic study ofFrontiers in genetics · 2025Article
- TFE3 immunohistochemistry in renal cell carcinomas: Does the clone really matter?Northern clinics of Istanbul · 2025Article
- Metastatic MiT family/TFE translocation renal cell carcinoma in adults: case series reports and literature reviews.Frontiers in oncology · 2025Article
- Papillary renal neoplasm with reverse polarity and renal clear cell carcinoma: a case report of image-pathology-molecular multidimensional diagnosis and nephron sparing surgery practice.Frontiers in oncology · 2025Article
- Case Report: Clinical pathological characteristics, diagnosis, and treatment analysis of eosinophilic solid and cystic renal cell carcinoma: experience from a five-case series.Frontiers in oncology · 2025Article
- Article
- Unveiling the Role of Human Papillomavirus in Urogenital Carcinogenesis a Comprehensive Review.Viruses · 2024Review
- Papillary renal neoplasm with reverse polarity: an observational study of histology, immunophenotypes, and molecular variation.Translational andrology and urology · 2024Article
- Case Report: AFrontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microphthalmia-associated transcription factor/transcription factor E (MiT/TFE) family of transcription factors are evolutionarily conserved, basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factors, consisting of MITF, TFEB, TFE3, and TFEC. MiT/TFE proteins, with the exception of TFEC, are involved in the development of renal cell carcinoma (RCC). Most of the MiT/TFE transcription factor alterations seen in sporadic RCC cases of MiT family translocation renal cell carcinoma (tRCC) are chimeric proteins generated by chromosomal rearrangements. These chimeric MiT/TFE proteins retain the bHLH-Zip structures and act as oncogenic transcription factors. The germline variant of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.